Skip to main content

Advertisement

SpringerLink
Log in

Alterations of the Gut Microbiome in Recurrent Malignant Gliomas Patients Received Bevacizumab and Temozolomide Combination Treatment and Temozolomide Monotherapy

  • Original research article
  • Published:
Indian Journal of Microbiology Aims and scope Submit manuscript

Abstract

This case-control study explored compositions of gut microbiome in recurrent malignant gliomas patients who had received bevacizumab and Temozolomide combination treatment and Temozolomide monotherapy. We investigated gut microbiota communities in feces of 29 recurrent malignant gliomas patients received combination treatment with bevacizumab and Temozolomide (Group 1) and monotherapy with Temozolomide alone (Group 2). We took advantage of the high-throughput Illumina Miseq sequencing technology by targeting the third and fourth hypervariable (V3–V4) regions of the 16S ribosomal RNA (rRNA) gene. We found that the structures and richness of the fecal microbiota in Group 1 were different from Group 2 with LEfSe analysis. The fecal microbiota in both Group 1 and Group 2 were mainly composed by Firmicutes, Proteobacteria, Bacteroidetes and Actinobacteria. However, Group 1 patients had higher relative abundance of Firmicutes, Bacteroidetes, Actinobacteria and lower relative abundance of Bacteroidetes and Cyanobacteria in their fecal microbiota than that in Group 2 patients. To evaluate bevacizumab involved post-treatment state of the fecal microbiota profile, we used random forest predictive model and ensembled decision trees with an AUC of 0.54. This study confirmed that the gut microbiota was different in recurrent malignant gliomas patients received the combination therapy of bevacizumab and Temozolomide compared with Temozolomide monotherapy. Our discover can help better understand the influence of bevacizumab related treatment on recurrent malignant gliomas patients. Therefore, this finding may also support the potentially therapeutic options for recurrent malignant gliomas patients such as fecal microbiota transplant.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

Data availability

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

References

  1. Tan AC, Ashley DM, Lopez GY, Malinzak M, Friedman HS, Khasraw M (2020) Management of glioblastoma: state of the art and future directions. CA Cancer J Clin 70:299–312. https://doi.org/10.3322/caac.21613

    Article  PubMed  Google Scholar 

  2. Wick W, Osswald M, Wick A, Winkler F (2018) Treatment of glioblastoma in adults. Ther Adv Neurol Disord 11:1756286418790452. https://doi.org/10.1177/1756286418790452

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Nishikawa R (2010) Standard therapy for glioblastoma–a review of where we are. Neurol Med Chir (Tokyo) 50:713–719. https://doi.org/10.2176/nmc.50.713

    Article  Google Scholar 

  4. Geribaldi-Doldan N, Hervas-Corpion I, Gomez-Oliva R et al (2021) Targeting protein kinase C in glioblastoma treatment. Biomedicines. https://doi.org/10.3390/biomedicines9040381

    Article  PubMed  PubMed Central  Google Scholar 

  5. Agirman G, Hsiao EY (2021) SnapShot: the microbiota-gut-brain axis. Cell 184:e2521. https://doi.org/10.1016/j.cell.2021.03.022

    Article  CAS  Google Scholar 

  6. Kincaid HJ, Nagpal R, Yadav H (2021) Diet-microbiota-brain axis in Alzheimer’s disease. Ann Nutr Metab. https://doi.org/10.1159/000515700

    Article  PubMed  Google Scholar 

  7. Polak K, Bergler-Czop B, Szczepanek M, Wojciechowska K, Fratczak A, Kiss N (2021) Psoriasis and gut microbiome-current state of art. Int J Mol Sci. https://doi.org/10.3390/ijms22094529

    Article  PubMed  PubMed Central  Google Scholar 

  8. Gong S, Feng Y, Zeng Y et al (2021) Gut microbiota accelerates cisplatin-induced acute liver injury associated with robust inflammation and oxidative stress in mice. J Transl Med 19:147. https://doi.org/10.1186/s12967-021-02814-5

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Kalia VC, Patel SKS, Cho BK, Wood TK, Lee JK (2021) Emerging applications of bacteria as antitumor agents. Semin Cancer Biol. https://doi.org/10.1016/j.semcancer.2021.05.012

    Article  PubMed  Google Scholar 

  10. Zhou CB, Zhou YL, Fang JY (2021) Gut microbiota in cancer immune response and immunotherapy. Trends Cancer. https://doi.org/10.1016/j.trecan.2021.01.010

    Article  PubMed  Google Scholar 

  11. Woelk CH, Snyder A (2021) Modulating gut microbiota to treat cancer. Science 371:573–574. https://doi.org/10.1126/science.abg2904

    Article  CAS  PubMed  Google Scholar 

  12. Strati F, Pujolassos M, Burrello C et al (2021) Antibiotic-associated dysbiosis affects the ability of the gut microbiota to control intestinal inflammation upon fecal microbiota transplantation in experimental colitis models. Microbiome 9:39. https://doi.org/10.1186/s40168-020-00991-x

    Article  PubMed  PubMed Central  Google Scholar 

  13. Gola A, Dorrington MG, Speranza E et al (2021) Commensal-driven immune zonation of the liver promotes host defence. Nature 589:131–136. https://doi.org/10.1038/s41586-020-2977-2

    Article  CAS  PubMed  Google Scholar 

  14. Breuninger TA, Wawro N, Breuninger J et al (2021) Associations between habitual diet, metabolic disease, and the gut microbiota using latent Dirichlet allocation. Microbiome 9:61. https://doi.org/10.1186/s40168-020-00969-9

    Article  PubMed  PubMed Central  Google Scholar 

  15. Vander Wyst KB, Ortega-Santos CP, Toffoli SN, Lahti CE, Whisner CM (2021) Diet, adiposity, and the gut microbiota from infancy to adolescence: a systematic review. Obes Rev 22:e13175. https://doi.org/10.1111/obr.13175

    Article  PubMed  Google Scholar 

  16. Rishi P, Thakur K, Vij S et al (2020) Diet, gut microbiota and COVID-19. Indian J Microbiol. https://doi.org/10.1007/s12088-020-00908-0

    Article  PubMed  PubMed Central  Google Scholar 

  17. Patel SKS, Lee JK, Kalia VC (2020) Deploying biomolecules as Anti-COVID-19 agents. Indian J Microbiol 60:263–268. https://doi.org/10.1007/s12088-020-00893-4

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Abellan-Schneyder I, Matchado MS, Reitmeier S et al (2021) Primer, pipelines, parameters: issues in 16S rRNA gene sequencing. msphere. https://doi.org/10.1128/mSphere.01202-20

    Article  PubMed  PubMed Central  Google Scholar 

  19. Jain T, Boland T, Lilov A et al (2017) Prediction of delayed retention of antibodies in hydrophobic interaction chromatography from sequence using machine learning. Bioinformatics 33:3758–3766. https://doi.org/10.1093/bioinformatics/btx519

    Article  CAS  PubMed  Google Scholar 

  20. Riquelme E, Zhang Y, Zhang L et al (2019) Tumor microbiome diversity and composition influence pancreatic cancer outcomes. Cell 178:e712. https://doi.org/10.1016/j.cell.2019.07.008

    Article  CAS  Google Scholar 

  21. Olah C, Varadi M, Horvath O, Nyirady P, Szarvas T (2021) Oncological relevance of gut and urine microbiomes. Orv Hetil 162:579–586. https://doi.org/10.1556/650.2021.32052

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

All colleagues collaborated in the collection and interpretation of the data and contributed to the manuscript.

Funding

Not applicable.

Author information

Authors and Affiliations

  1. Department of General Practice, School of Medicine, The Fourth Affiliated Hospital, Zhejiang University, Yiwu, Zhejiang Province, China

    Junwei Zhu

  2. Department of Radiology, School of Medicine, The Fourth Affiliated Hospital, Zhejiang University, Yiwu, Zhejiang Province, China

    Jun Su

Authors
  1. Junwei Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jun Su
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

JZ collected the samples, wrote the manuscript, prepared the figures. JS edited the manuscript.

Corresponding author

Correspondence to Junwei Zhu.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Consent to Participate

Written informed consent for the study was obtained from each patient involved in the study after oral notification.

Consent for Publication

Written consent for publication was obtained from all the patients involved in our study. No identifiable individual patient or health person was involved in this study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (RAR 8072 kb)

Supplementary file2 (DOCX 18 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhu, J., Su, J. Alterations of the Gut Microbiome in Recurrent Malignant Gliomas Patients Received Bevacizumab and Temozolomide Combination Treatment and Temozolomide Monotherapy. Indian J Microbiol 62, 23–31 (2022). https://doi.org/10.1007/s12088-021-00962-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12088-021-00962-2

Keywords

Search

Navigation